Dongwei Zhang^1,2 , Jiayu Zhang¹

1 Department of Breast Surgery, the Second Affiliated of Harbin Medical University, Harbin, Heilongjiang, China
2 Heilongjiang academy of medical sciences, Harbin, Heilongjiang, China
Author    Correspondence author
Cancer Genetics and Epigenetics, 2018, Vol. 6, No. 2   doi: 10.5376/cge.2018.07.0002
Received: 25 May, 2018    Accepted: 05 Jun., 2018    Published: 01 Aug., 2018

This is an open access article published under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Zhang J.Y., and Zhang D.W., 2018, Diagnosis and treatment of triple negative breast cancer, 6(2): 13-18 (doi: 10.5376/cge.2018.06.0002)

Triple negative breast cancer is a subtype of breast cancer, which has the characteristics of easy invasion, high recurrence rate and short survival period. Local surgery and systemic chemotherapy are the main treatment methods for triple negative breast cancer. The toxicity of chemotherapy is severe, and the tumor will recur and metastasize quickly once it is resistant. At present, the main research directions of triple negative breast cancer are new targeted therapy, immunotherapy and new endocrine therapy. This article reviews the research progress of triple negative breast cancer.

Triple negative breast cancer; Targeted therapy; Immunization therapy